4/ Thank you to our booth speakers from Baptist Health South Florida, Henry Ford Health, Gemelli, UCLA Health, Stanford Medicine, City of Hope, UZ Brussel & Assuta Medical Center. Your work inspires us.
1/ Radiotherapy re-envisioned.
Thank you to everyone who visited ViewRay at #ASTRO2026, where we introduced 6 new 510(k)-pending products: MRI-guided (0.35 T & 0.12 T) and spectral CT-guided linacs, each with a matching simulator.
Not available for sale in the US.
3/ In the randomized phase III MIRAGE trial (prostate, 2-yr follow-up), MRI-guided radiotherapy with ViewRay SMARTTARGETยฎ technology allowed tighter margins and significantly reduced side effects (Kishan, Amar U., et al. JAMA oncology 9.3 (2023): 365-373.).
Breaking News: ViewRay Systems, Inc. announces 510(k) pending status of next-generation innovations.
See our new portfolio this week at #ASTRO2026 in Boston, Booth #2810/2910. Meetings: [email protected]
510(k) pending. Not available for sale in the U.S.
ViewRay is back at #ASTRO26! Leaders in MRI-guided radiotherapy present their clinical programs and research at Booth #2810/2910, Sept 27โ29. Schedule below ๐ #MRgRT#RadOnc
There are no blind surgeons. Radiotherapy shouldn't be either. ViewRay provides the visually guided margins you need.
Seeing: it's a good idea.
ViewRay is back. Booth #2810/2910 at #ASTRO26, Boston. Book a meeting: [email protected]#MRgRT#RadOnc